CN118221777A - Polypeptide for repairing skin wound or mucous membrane injury and application thereof - Google Patents
Polypeptide for repairing skin wound or mucous membrane injury and application thereof Download PDFInfo
- Publication number
- CN118221777A CN118221777A CN202410392675.9A CN202410392675A CN118221777A CN 118221777 A CN118221777 A CN 118221777A CN 202410392675 A CN202410392675 A CN 202410392675A CN 118221777 A CN118221777 A CN 118221777A
- Authority
- CN
- China
- Prior art keywords
- leu
- gly
- val
- ser
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010072170 Skin wound Diseases 0.000 title claims abstract description 22
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 60
- 229920001184 polypeptide Polymers 0.000 title abstract description 52
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 52
- 208000027418 Wounds and injury Diseases 0.000 title abstract description 38
- 230000006378 damage Effects 0.000 title abstract description 23
- 208000014674 injury Diseases 0.000 title abstract description 15
- 210000004400 mucous membrane Anatomy 0.000 title abstract description 15
- 208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 44
- 208000025865 Ulcer Diseases 0.000 claims description 26
- 231100000397 ulcer Toxicity 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 229940126214 compound 3 Drugs 0.000 claims description 5
- 229940125898 compound 5 Drugs 0.000 claims description 5
- 229940125782 compound 2 Drugs 0.000 claims description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims description 3
- 206010053615 Thermal burn Diseases 0.000 claims description 3
- 206010040882 skin lesion Diseases 0.000 claims description 3
- 231100000444 skin lesion Toxicity 0.000 claims description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 claims description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 claims description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 claims description 2
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 claims description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 claims description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 claims description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 claims description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 claims description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 claims description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 claims description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 claims description 2
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 claims description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims description 2
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 claims description 2
- 206010016717 Fistula Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims description 2
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 2
- 208000002847 Surgical Wound Diseases 0.000 claims description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 claims description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 claims description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims description 2
- 229940125773 compound 10 Drugs 0.000 claims description 2
- 229940125797 compound 12 Drugs 0.000 claims description 2
- 229940125810 compound 20 Drugs 0.000 claims description 2
- 229940126086 compound 21 Drugs 0.000 claims description 2
- 229940125833 compound 23 Drugs 0.000 claims description 2
- 229940125846 compound 25 Drugs 0.000 claims description 2
- 229940125877 compound 31 Drugs 0.000 claims description 2
- 229940125878 compound 36 Drugs 0.000 claims description 2
- 229940125807 compound 37 Drugs 0.000 claims description 2
- 229940125936 compound 42 Drugs 0.000 claims description 2
- 229940127271 compound 49 Drugs 0.000 claims description 2
- 229940126545 compound 53 Drugs 0.000 claims description 2
- 230000003890 fistula Effects 0.000 claims description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000011127 radiochemotherapy Methods 0.000 claims description 2
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 claims 1
- 229940126639 Compound 33 Drugs 0.000 claims 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 claims 1
- 229940125851 compound 27 Drugs 0.000 claims 1
- 229940127573 compound 38 Drugs 0.000 claims 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 201000005917 gastric ulcer Diseases 0.000 abstract description 6
- 230000004663 cell proliferation Effects 0.000 abstract description 4
- 230000024245 cell differentiation Effects 0.000 abstract description 2
- 208000010643 digestive system disease Diseases 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 230000001276 controlling effect Effects 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 65
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 48
- 238000005160 1H NMR spectroscopy Methods 0.000 description 37
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 34
- 238000004896 high resolution mass spectrometry Methods 0.000 description 29
- 210000003491 skin Anatomy 0.000 description 24
- 206010052428 Wound Diseases 0.000 description 23
- 238000000034 method Methods 0.000 description 23
- 229940125904 compound 1 Drugs 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 150000001413 amino acids Chemical group 0.000 description 16
- 238000012217 deletion Methods 0.000 description 16
- 230000037430 deletion Effects 0.000 description 16
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 15
- 101800003838 Epidermal growth factor Proteins 0.000 description 15
- 229940116977 epidermal growth factor Drugs 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 14
- 230000035755 proliferation Effects 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 11
- 230000002496 gastric effect Effects 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 208000023652 chronic gastritis Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 230000029663 wound healing Effects 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 8
- 210000001156 gastric mucosa Anatomy 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 230000009854 mucosal lesion Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 208000018522 Gastrointestinal disease Diseases 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000008469 Peptic Ulcer Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 208000028299 esophageal disease Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 229920000153 Povidone-iodine Polymers 0.000 description 4
- 208000028990 Skin injury Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 4
- 239000008098 formaldehyde solution Substances 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 229960001621 povidone-iodine Drugs 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 208000011906 peptic ulcer disease Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 2
- DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical group CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 2
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 2
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- FZQLXNIMCPJVJE-YUMQZZPRSA-N Gly-Asp-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FZQLXNIMCPJVJE-YUMQZZPRSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010030201 Oesophageal ulcer Diseases 0.000 description 2
- 206010030216 Oesophagitis Diseases 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000012876 acute enteritis Diseases 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 208000021735 chronic enteritis Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 208000019064 esophageal ulcer Diseases 0.000 description 2
- 208000006881 esophagitis Diseases 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical group O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 1
- SCCPDJAQCXWPTF-VKHMYHEASA-N Gly-Asp Chemical compound NCC(=O)N[C@H](C(O)=O)CC(O)=O SCCPDJAQCXWPTF-VKHMYHEASA-N 0.000 description 1
- KQDMENMTYNBWMR-WHFBIAKZSA-N Gly-Asp-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O KQDMENMTYNBWMR-WHFBIAKZSA-N 0.000 description 1
- XBWMTPAIUQIWKA-BYULHYEWSA-N Gly-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN XBWMTPAIUQIWKA-BYULHYEWSA-N 0.000 description 1
- TZOVVRJYUDETQG-RCOVLWMOSA-N Gly-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN TZOVVRJYUDETQG-RCOVLWMOSA-N 0.000 description 1
- BEQGFMIBZFNROK-JGVFFNPUSA-N Gly-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)O BEQGFMIBZFNROK-JGVFFNPUSA-N 0.000 description 1
- GDOZQTNZPCUARW-YFKPBYRVSA-N Gly-Gly-Glu Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O GDOZQTNZPCUARW-YFKPBYRVSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 1
- LAPSXOAUPNOINL-YUMQZZPRSA-N Leu-Gly-Asp Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O LAPSXOAUPNOINL-YUMQZZPRSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003651 pro-proliferative effect Effects 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a novel polypeptide for repairing skin wounds or mucous membrane injuries and application thereof, and a series of polypeptides of the invention have no homology with known polypeptides and have the effect of regulating and controlling cell proliferation and differentiation; and relates to the application of the novel polypeptide in repairing mucous membrane injury or skin wound and the application in preventing, reducing or treating gastroenteropathy such as gastritis, gastric ulcer and the like.
Description
The application relates to polypeptide for repairing skin wounds or mucous membrane injuries and application of the polypeptide, which are applied to the application number 2021109849080 and the application date 2021.08.25.
Technical Field
The invention relates to a novel polypeptide for repairing skin wounds or mucous membrane injuries and application thereof, wherein the polypeptide has no homology with known polypeptides and has the effect of repairing mucous membrane injuries or skin injuries.
Background
Skin wounds and/or mucosal lesions are common pathological features of many diseases. Skin wounds or skin lesions refer to damage to normal skin (tissue) caused by external wound factors such as surgery, external force, heat, electric current, chemicals, low temperature, and internal factors of the body such as local blood supply disorder. Skin damage is often accompanied by a disruption of the integrity of the skin and loss of a certain amount of normal tissue, while at the same time, the normal function of the skin is impaired. Also known as a wound or trauma. At present, protein/polypeptide medicines comprising alkaline fibroblast growth factor, epidermal growth factor, platelet growth factor, granulocyte-macrophage colony stimulating factor, growth hormone and the like have obvious effects of repairing wound surfaces, protecting skin, resisting wrinkles and resisting aging, but the protein/polypeptide medicines have the defects of high preparation cost, poor stability and the like due to longer amino acid sequences, so the application of the protein/polypeptide medicines is limited to a certain extent.
Epidermal Growth Factor (EGF) is a polypeptide consisting of 53 amino acid residues, which is widely present in various tissues, organs and body fluids, and which promotes proliferation of epithelial cells to protect the skin. The epidermal growth factor is mainly used for promoting the proliferation and growth of skin tissue cells, so that new cells replace aged cells, thereby having the functions of resisting aging, protecting skin, protecting health and the like. Epidermal growth factor has been reported to have wound repairing effect, and EGF is unstable under such conditions because iodine or hydrogen peroxide-containing disinfectants are applied when skin wound needs to be disinfected and debrided. Growth factors are involved in gastrointestinal healing (j. Surgic Res).
2014; 17:202-210), EGF is degraded after being taken into the body by gastrointestinal oral administration, and the therapeutic effect cannot be achieved in experiments.
The human mucosa refers to the inner layer of the lumen tract or saccular muscle organs of the respiratory system, the digestive system, the genitourinary system, and the like, is the second largest barrier of the human body next to the skin, comprises the oral cavity, the pharynx, the trachea, the esophagus, the stomach, the intestinal tract, the vagina, the bladder, and the like, has common layering rules of the tube walls or the capsule walls of the organs, has the characteristics of adapting to the functions of the organs, and has common characteristics of embryo origin, tissue structure, pathological process, clinical manifestation, post-healing, and the like.
Chronic gastritis is a chronic inflammation of gastric mucosa, is a common disease and frequently-occurring disease of digestive system department, and clinically chronic inflammation of gastric mucosa (i.e. pathologically expressed as mononuclear cell and lymphocyte infiltration) and/or glandular atrophy lesion caused by different causes are called chronic gastritis. Damage to mucosal tissue clinically results in gastrointestinal disorders such as chronic gastritis and peptic ulcer. Repair of mucosal epithelium has two distinct mechanisms, repair (regeneration or renewal) (cur. Med. Chem.,2008,15,3133-3144): repair or restoration generally begins within minutes after the injury, rapidly repairing the superficial lesions by cell migration; regeneration is the continuous regeneration through differentiation and proliferation of stem and progenitor cells for days to months. The medicine for treating acute and chronic gastritis and peptic ulcer mainly comprises gastric acid inhibitor, gastric mucosa protectant, antibiotics and other small molecular compounds, has limited treatment effect, protects and promotes the repair of damaged mucous membrane, is the key point for treating acute and chronic gastritis and peptic ulcer, and the gastric mucosa protectant mainly plays a role in protecting the damaged mucous membrane and has tissue repair effect. The gastric mucosa protective medicine has the problems of limited treatment effect, poor effectiveness, long treatment course, high recurrence rate and the like in the clinical application process, and can not meet the clinical treatment requirements of acute and chronic gastritis and digestive tract ulcer caused by various reasons, so that the research and development of medicines with better protection and tissue repair on digestive tract mucosa are very necessary, and the polypeptide medicines have the characteristics of strong biological activity and high safety, and the screening, discovery and development of the polypeptide medicines capable of treating skin injury and capable of treating mucosal injury through oral administration are significant.
Disclosure of Invention
In order to overcome the defects and shortcomings of the prior art, the invention aims to provide novel polypeptides.
In a first aspect, the present invention provides a compound of formula (I) or a physiologically compatible salt thereof, wherein the compound of formula (I) is as follows:
H-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Val-Thr-Val-Ser-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-OH
wherein X aa1 is Pro or deleted;
X aa2 is Val or deletion;
X aa3 is Lys, pro or deletion;
X aa4 is Leu, val, ala or a deletion;
x aa5 is Lys, arg or deletion;
X aa6 is Ser, thr, ala or a deletion;
X aa7 is Lys, arg or deletion;
x aa8 is Leu, val, ala, ile or a deletion;
x aa9 is Gly, pro, ala or a deletion;
X aa10 is Asp, glu, asn, val or a deletion;
X aa11 is Leu, val, ala, ile, pro or a deletion;
X aa12 is Leu, val, ala or a deletion;
x aa13 is Pro, ala, gly, val or a deletion;
x aa14 is Gly, ala or deletion;
x aa15 is Gly, ala or deletion;
X aa16 is Glu, gln, asp or a deletion;
X aa17 is Glu, asp, gln or a deletion.
In one embodiment, X aa1 is absent.
In one embodiment, X aa2 is absent.
In one embodiment, both X aa1 and X aa2 are absent.
In one embodiment, X aa4-Xaa5-Xaa6-Xaa7 is Leu-Lys-Ser-Lys. In one embodiment of the present invention, in one embodiment,
X aa4-Xaa5-Xaa6-Xaa7-Xaa8 is Leu-Lys-Ser-Lys-Leu. In one embodiment, X aa4-Xaa5-Xaa6-Xaa7-Xaa8 is Lys-Ser-Lys-Leu, wherein X aa4 is absent.
In one embodiment, X aa9-Xaa10 is Gly-Asp. In one embodiment, X aa9-Xaa10-Xaa11 is Gly-Asp-Leu. In one embodiment, X aa9-Xaa10-Xaa11 is Gly-Asp-Val, gly-Asp-Ala or Gly-Asp-Ile.
In one embodiment, X aa12 is Leu, val, or Ala, preferably Leu.
In one embodiment, X aa13-Xaa14 is Pro-Gly. In one embodiment, X aa13-Xaa14-Xaa15 is Pro-Gly-Gly. In one embodiment, X aa13-Xaa14-Xaa15-Xaa16-Xaa17 is Pro-Gly-Gly-Glu-Glu. In one embodiment of the present invention, in one embodiment,
X aa13-Xaa14-Xaa15-Xaa16-Xaa17 is Ala-Gly-Gly-Glu-Glu、Gly-Gly-Gly-Glu-Glu、Pro-Gly-Gly-Glu-Asp、Pro-Gly-Gly-Gln-Glu、Pro-Gly-Gly-Glu-Gln、Pro-Gly-Gly-Asp-Asp、Pro-Ala-Ala-Asp-Asp、Val-Gly-Gly-Glu-Glu or Pro-Ala-Ala-Gln-Gln.
For convenience, in describing the compounds of the present application, the left-hand H and the right-hand OH are omitted.
In a second aspect, the present invention provides a method of repairing a skin wound, the method comprising contacting the skin wound with a compound of the invention or a physiologically compatible salt thereof. In a preferred embodiment, the skin wound is associated with, but not limited to, epidermal inflammation, mechanical and surgical wounds, burns and scalds, ulcers, fistulas, bedsores, and skin lesions caused by chemoradiotherapy. In one embodiment, the skin wound refers to damage of normal skin caused by external injury factors such as surgery, external force, heat, electric current, chemicals, low temperature, and factors inherent in the body such as local blood supply disorder. In one embodiment, the skin wound is accompanied by a disruption of the integrity of the skin and a loss of a certain amount of normal tissue. In another embodiment, the skin wound comprises an impaired normal function of the skin.
The present invention provides a method of promoting HaCAT cell proliferation comprising contacting the cell with a compound of the invention or a physiologically compatible salt thereof.
In a third aspect, the invention provides a method of repairing mucosal lesions, the method comprising administering to a subject a compound of the invention or a physiologically compatible salt thereof or contacting mucosal lesions with a compound of the invention or a physiologically compatible salt thereof.
In one embodiment, the mucosal lesion is a mucosal lesion in the lumen of the digestive system, respiratory system, etc.
Digestive system mucosal lesions are associated with oral, esophageal, gastrointestinal diseases including canker sores, stomatitis, gingivitis, periodontitis, and the like; the esophagus diseases comprise esophagitis, esophageal ulcer and the like; the gastrointestinal diseases comprise chronic gastritis, chronic atrophic gastritis, acute gastritis, gastroduodenal ulcer, functional gastrointestinal diseases, dyspepsia, precancerous lesions, digestive system tumors, gastrointestinal bleeding, gastroesophageal reflux diseases, acute and chronic enteritis, ulcerative colitis, crohn's disease and mucous membrane damage caused by radiotherapy and chemotherapy, but are not limited to the above.
In a preferred embodiment, the digestive tract mucosa comprises gastric mucosa and intestinal mucosa. In a preferred embodiment, the mucosal lesion is a gastric mucosal lesion caused by a irritating substance or drug, a stress state. Such as hydrochloric acid, ethanol or alcohol, etc., and such as non-steroidal anti-inflammatory drugs, such as aspirin or indomethacin, etc.
The present invention provides a method of preventing, reducing or treating a digestive tract disease or eliminating inflammatory oedema comprising administering to a subject a compound of the invention or a physiologically compatible salt thereof. The digestive tract diseases comprise oral cavity, esophagus and gastrointestinal diseases, and the oral cavity diseases comprise oral ulcer, stomatitis, gingivitis, periodontitis and the like; the esophagus diseases comprise esophagitis, esophageal ulcer and the like; the gastrointestinal diseases comprise chronic gastritis, chronic atrophic gastritis, acute gastritis, gastroduodenal ulcer, functional gastrointestinal diseases, dyspepsia, precancerous lesions, digestive system tumors, gastrointestinal bleeding, gastroesophageal reflux diseases, acute and chronic enteritis, ulcerative colitis, crohn's disease and mucous membrane damage caused by radiotherapy and chemotherapy; but is not limited thereto. In one embodiment, the prevention, alleviation or treatment of the digestive tract disease is by modulating stem cell proliferation and differentiation. The compound or the physiologically compatible salt thereof plays a role in protecting or repairing the damage of the digestive tract mucous membrane such as gastric mucous membrane or intestinal mucous membrane, thereby playing a role in preventing, reducing or treating gastrointestinal diseases.
The present invention provides a method of repairing a mucosal or dermal wound comprising administering to a subject a compound of the invention or a physiologically compatible salt thereof.
In the above-described method of the present invention, the compound of the present invention or a physiologically compatible salt thereof is administered orally, by injection, subcutaneously, or the like.
In a fourth aspect, the present invention provides a pharmaceutical, food, nutraceutical or cosmetic, commodity composition comprising a compound of the present invention or a physiologically compatible salt thereof and a physiologically acceptable carrier. In one embodiment, the physiologically acceptable carrier comprises a pharmaceutically acceptable carrier or a cosmetically acceptable carrier. The pharmaceutical, nutraceutical or cosmetic, commodity composition may be prepared according to conventional techniques of pharmacy or cosmetics, comprising mixing the compound of the invention as active ingredient with a carrier, and formulating into the desired dosage form according to conventional techniques. The composition of the present invention can be formulated into oral administration preparations, mucosal administration preparations, injection preparations, inhalation preparations and external preparations as needed.
The polypeptide of the invention has no homology with the known polypeptide, is convenient for artificial polypeptide synthesis to obtain high-purity polypeptide, and is only composed of at most 21 amino acid residues compared with the epidermal growth factor polypeptide, and has obvious effects of eliminating inflammatory edema, promoting repair of gastrointestinal mucosal injury and relieving pathological development of gastrointestinal diseases such as acute and chronic gastritis and peptic ulcer after oral administration; has effects in promoting skin wound repair, shortening wound healing time, and regulating immunity. Oral administration can also work. In addition, the polypeptide can act even after being disinfected by an iodine preparation or hydrogen peroxide when being used for the wound surface of the body surface skin, and the structure is damaged after being disinfected by the iodine preparation or hydrogen peroxide when the epidermal growth factor is used for the body surface skin, so that the polypeptide cannot act.
Detailed Description
The term "physiologically compatible salt" refers to a salt form that is physiologically compatible (i.e., pharmacologically acceptable) and that is substantially non-toxic to the individual to whom the compounds of the present invention are to be administered. Physiologically compatible salts of the compounds of the invention include the conventional and stoichiometric acid or base addition salts formed with suitable, non-toxic organic or inorganic acids or inorganic bases.
It will be appreciated by those skilled in the art that the repair of skin wounds and/or mucosal lesions of the present application may be administered for cosmetic (i.e., non-therapeutic) and therapeutic purposes. To this end, the term "skin injury" according to the application includes, in addition to skin damage, burns, scalds, etc., skin injuries repaired for cosmetic purposes such as wrinkles (e.g., wrinkles resulting from ultraviolet radiation), skin lines, fissures, bumps, large pores (e.g., associated with accessory structures such as sweat gland ducts, sebaceous glands or hair follicles), or uneven or rough skin, loss of elasticity (loss and/or inactivation of functional skin elastin), sagging (including eye and mandibular edema), loss of skin firmness, loss of resilience after skin deformation, discoloration (including dark circles), blisters, sallowness of the skin, excessive pigment skin areas such as age spots and freckles, keratinous materials, abnormal differentiation, excessive keratinization, elastosis, destruction of collagen, and skin keratin, dermis, epidermis, skin vascular system (e.g., telangiectasia or multi-forked blood vessels), and other tissue changes in subcutaneous tissue, especially in the subcutaneous tissue adjacent to the skin.
Examples
The following is a description of the invention in connection with specific experiments and is not intended to limit the scope of the invention.
Example 1: chemical synthesis of polypeptides
The synthesis of polypeptide compound adopts conventional solid phase synthesis method, and adopts the processes of resin swelling, substitution, deprotection, washing, amino acid dissolution, amino acid activation and condensation, washing, deprotection again and several circulation processes, and finally cleavage and side chain deprotection.
Example 1: chemical synthesis of polypeptides
The synthesis of polypeptide compound adopts conventional solid phase synthesis method, and adopts the processes of resin swelling, substitution, deprotection, washing, amino acid dissolution, amino acid activation and condensation, washing, deprotection again and several circulation processes, and finally cleavage and side chain deprotection. The reaction scheme for solid phase synthesis is as follows:
TABLE 1 Chinese and English abbreviations for solvents, reagents, etc
Synthetic examples:
1) Preparation of full-protection peptide resin of Compound 1 (Leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu)
(1) Swelling of the resin: 2-Chlorotrityl Chloride Resin 6.94.94 g (SD=0.65 mmol/g) was weighed into a sieve plate synthesis tube and swollen with 100ml Dichloromethane (DCM).
(2) Fmoc-Glu (OtBu) -resin was prepared: fmoc-Glu (OtBu) -OH.H 2 O, DIPEA was weighed separately in a molar ratio of 1:2:5.38 into a synthesis tube as resin, fmoc-Glu (OtBu) -OH.H 2 O, DIPEA. Bubbling and vibrating at room temperature N 2 for 1-3 hours, and draining; the resin was then drained by washing 5 times with Dimethylformamide (DMF), 100 ml/time, respectively.
(3) Removing Fmoc protecting groups: adding 100ml of 20% piperidine-DMF (v/v) solution into a reactor, bubbling N 2 for 20min, and pumping out; fmoc removal was then checked by DMF washing 5 times, 100 ml/time, 3 minutes/time, draining and ninhydrin method.
(4) Amino acid pre-activation: 13.5mmol of Fmoc protected amino acid, 13.5mmol of HOBt, 13.5mmol of DIC were added to a 250ml beaker and dissolved in 100ml of DMF and kept at room temperature.
(5) Amino acid linkage: the activated protected amino acid solution was poured into the reactor and an appropriate amount of DCM washware was added. N 2 is bubbled for 1 to 3 hours at room temperature, and the ninhydrin method is used for detecting whether the amino acid connection is complete or not, and if the amino acid connection is complete, the amino acid connection is pumped out. The resin was washed 5 times with DMF, 100 ml/time, 3 min/time and drained. The amounts of each amino acid and condensing agent are shown in Table 2.
(6) After the first amino acid condensation is completed, repeating the steps (4) and (5), and extending the peptide chain to the last amino acid coupling according to the amino acid sequence.
(7) The resin peptide was washed 4 times with DMF, 150 ml/time, 3 min/time; further washed 3 times with DCM, 150 ml/time, 3 min/time and drained.
TABLE 2 amino acid and condensing agent dosage
2) Cutting
(1) A cleavage reagent (TFA: TIS: H 2O=95:2.5:2.5,v/v)100ml,N2 bubbling reaction was added to the synthesis tube for 1.5 to 3 hours.
(2) After the cleavage reaction was completed, the cleavage agent was suction filtered into a 250ml round bottom flask. After concentrating in vacuo to one fourth of the original cutter volume, 10 times the existing volume of methyl tert-butyl ether was added and a white solid was obtained by settling. The resulting mixed solvent was filtered and washed 3 times with 50ml of methyl tert-butyl ether, respectively, and the resulting crude peptide product was dried in a sand core funnel in a fume hood with N 2 to evaporate the solvent to a powder form. 7.39g of crude peptide was obtained in 89.0% crude yield.
3) Purification, salt exchange and lyophilization
(1) Polypeptide HPLC purification preparation
A. Chromatographic parameters
Chromatographic column: dynamic axial compression column 80 x 250mm, packing: daisogel C18 (SP-100-8-ODS-P)
Eluent a:10mM ammonium bicarbonate aqueous solution
Eluent B: acetonitrile
Flow rate: 180ml/min
Ultraviolet detection wavelength: 220nm
B. operating procedure
A) The crude peptide was dissolved with water and/or acetonitrile and filtered through a 0.45 μm filter
B) Sample injection
C) Acetonitrile-water mobile phase gradient elution
D) Collecting target peptide eluent
E) Spin distillation and concentration
(2) Polypeptide HPLC salt (acetate)
Chromatographic parameters chromatographic column: dynamic axial compression column 80 x 250mm, packing: daisogel C18 (SP-100-8-ODS-P) eluent A1:0.1M acetic acid
Eluent A2:0.025M acetic acid-0.1M ammonium acetate
Eluent B: acetonitrile
Flow rate: 180ml/min
Ultraviolet detection wavelength: 220nm
Operating procedure
A) 95% A1+5% B equilibrium chromatographic column
B) Sample injection
C) 95% A2+5% B equilibrium chromatographic column
D) A1 and B gradient elution
E) Collecting target peptide eluent
F) Spin distillation and concentration
G) Freeze drying
TABLE 3 synthetic Compounds
Annotation: the double charge peak indicates that the target molecule binds 2 protons, and the three charge peaks indicates that the target molecule binds 3 protons; N/A represents the difficulty in weighing, not the actual weight.
Compound 1: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
High resolution mass spectrometry (TOF-HRMS), molecular formula :C81H140N20O28;m/z:921.52014([M+2H]2+),1842.03431([M+H]+).
1H NMR(600MHz,DMSO-d6)δ8.55(s,1H),8.46(s,2H),8.39(s,1H),8.14(s,6H),8.07–8.00(m,2H),7.98(d,J=7.9Hz,1H),7.74(s,2H),7.60(s,1H),4.57(d,J=7.9Hz,1H),4.47(d,J=7.0Hz,1H),4.34–4.19(m,8H),4.18–4.09(m,4H),3.97–3.91(m,2H),3.85–3.79(m,1H),3.73(d,J=11.8Hz,3H),3.68–3.55(m,7H),3.52(d,J=5.7Hz,3H),3.43(t,J=7.0Hz,1H),2.73(s,4H),2.21–2.09(m,4H),2.07–1.94(m,4H),1.92–1.64(m,19H,AcOH),1.63–1.38(m,16H),1.37–1.20(m,5H),1.01(d,J=6.2Hz,3H),0.90–0.74(m,36H). Compound 2: leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 60H100N14O23;m/z:1385.72297([M+H]+).
1H NMR(600MHz,DMSO-d6)δ8.72(s,1H),8.34(s,1H),8.29(d,J=7.3Hz,1H),8.17(s,1H),8.04(s,1H),8.02–7.93(m,5H),7.90(d,J=8.8Hz,1H),7.51(d,J=8.7Hz,1H),4.56(q,J=7.6Hz,1H),4.42(q,J=6.9Hz,1H),4.32–4.12(m,8H),4.08(q,J=7.0Hz,1H),3.96–3.93(m,1H),3.82–3.71(m,4H),3.68–3.62(m,5H),3.51(d,J=5.9Hz,3H),2.44–2.39(m,1H),2.23(dt,J=8.0,4.2Hz,4H),2.06–1.85(m,8H,AcOH),1.84–1.39(m,14H),0.99(d,J=6.3Hz,3H),0.89–0.78(m,31H).
Compound 3: gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
1H NMR(600MHz,DMSO-d6)δ8.52–8.33(m,3H),8.19(d,J=8.1Hz,1H),8.10–7.87(m,6H),7.53(d,J=8.8Hz,1H),4.60–4.51(m,2H),4.37–4.14(m,7H),4.11(t,J=6.4Hz,1H),4.06(q,J=7.1Hz,1H),3.97–3.90(m,1H),3.84–3.59(m,7H),3.54–3.42(m,6H),2.63–2.51(m,2H),2.22(t,J=7.8Hz,4H),2.07–1.66(m,11H,AcOH),1.66–1.47(m,4H),1.42(t,J=7.0Hz,2H),0.99(d,J=6.3Hz,3H),0.90–0.72(m,24H).
Compound 4: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu (acetate)
1H NMR(600MHz,D2O)δ4.62–4.60(m,1H),4.40(t,J=5.6Hz,1H),4.36(t,J=7.2Hz,1H),4.32–4.24(m,2H),4.18–4.11(m,1H),4.01–3.94(m,2H),3.87–3.77(m,3H),2.97–2.92(m,4H),2.75–2.69(m,1H),2.60–2.53(m,1H),1.95–1.93(m,7H,AcOH),1.84–1.53(m,17H),1.46–1.33(m,4H),0.91–0.85(m,12H),0.82(t,J=5.9Hz,6H).
Compound 5: val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
1H NMR(600MHz,DMSO-d6)δ8.45–8.41(m,1H),8.33–8.23(m,2H),8.04(t,J=8.8Hz,2H),7.99(t,J=6.0Hz,1H),7.85(d,J=6.9Hz,1H),7.74(d,J=8.8Hz,1H),4.58(q,J=7.8Hz,1H),4.38–4.27(m,3H),4.27–4.21(m,3H),4.08–3.91(m,3H),3.84–3.79(m,1H),3.72–3.60(m,5H),3.56–3.47(m,4H),3.46(d,J=5.0Hz,1H),2.22(q,J=7.9Hz,4H),2.07–1.95(m,4H),1.95–1.77(m,8H,AcOH),1.76–1.69(m,1H),1.63–1.55(m,1H),1.45–1.38(m,2H),1.03(d,J=6.2Hz,3H),0.90(d,J=6.8Hz,3H),0.86–0.83(m,9H),0.80(d,J=6.8Hz,3H),0.78(d,J=6.8Hz,3H).
Compound 6: leu-Pro-Gly-Gly-Glu
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 25H40N6O11;m/z:601.28438([M+H]+).
Compound 7: pro-Gly-Gly-Glu
1H NMR(600MHz,DMSO-d6)δ9.04(s,1H),8.50(d,J=7.6Hz,1H),8.20(s,1H),7.85–7.79(m,1H),4.15(q,J=7.2Hz,1H),3.93(q,J=6.8Hz,1H),3.90–3.80(m,3H),3.79–3.57(m,3H),3.16–2.83(m,3H),2.23–2.05(m,6H),1.91–1.77(m,4H).
Compound 8: val-Thr-Val-Ser (acetate)
1H NMR(600MHz,DMSO-d6+D2O+TFA)δ4.27(d,J=5.7Hz,1H),4.25–4.22(m,1H),4.15(d,J=6.6Hz,1H),3.91(p,J=6.2Hz,1H),3.71–3.64(m,2H),3.63–3.59(m,1H),2.08–2.00(m,1H),1.96(h,J=6.8Hz,1H),1.87(s,AcOH),1.04(d,J=6.4Hz,3H),0.86(dd,J=6.9,4.5Hz,6H),0.82–0.76(m,6H).
Compound 9: gly-Asp-Leu
1H NMR(600MHz,DMSO-d6+D2O+TFA)δ4.61(dd,J=8.6,4.6Hz,1H),4.17–4.11(m,1H),3.59–3.49(m,2H),2.71–2.64(m,1H),2.56–2.49(m,1H),1.60–1.42(m,3H),0.82(d,J=6.5Hz,3H),0.76(d,J=6.5Hz,3H).
Compound 10: leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 41H73N9O14;m/z:916.53883([M+H]+).
Compound 11: gly-Asp-Leu-Val-Thr-Val-Ser-Leu
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 35H62N8O13;m/z:803.45303([M+H]+).
Compound 12: val-Thr-Val-Ser-Leu-Pro (acetate)
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 28H50N6O9;m/z:615.37174([M+H]+).
1H NMR(600MHz,DMSO-d6+TFA)δ8.10(s,1H),7.97(d,J=7.9Hz,1H),7.86(d,J=8.1Hz,1H),7.71(d,J=8.7Hz,1H),4.55(q,J=7.9,7.5Hz,2H),4.32–4.23(m,2H),4.19(dd,J=8.6,4.3Hz,1H),4.08(s,1H),3.98(td,J=6.4,4.0Hz,1H),3.87(s,1H),3.65–3.58(m,2H),3.51(d,J=5.9Hz,1H),3.44(s,2H),3.26(s,1H),3.18(d,J=4.6Hz,1H),2.12–2.05(m,1H),2.03–1.93(m,3H),1.92–1.75(m,5H,AcOH),1.71–1.61(m,2H),1.52(s,1H),1.47–1.27(m,3H),1.01(d,J=6.3Hz,3H),0.88–0.82(m,12H),0.80–0.78(m,6H).
Compound 13: val-Thr-Val-Ser-Leu
1H NMR(600MHz,DMSO-d6+D2O+TFA)δ4.28(dd,J=7.3,5.4Hz,2H),4.19(dd,J=9.7,5.2Hz,1H),4.14(d,J=6.4Hz,1H),3.91(p,J=6.2Hz,1H),3.67(d,J=5.7Hz,1H),3.58–3.54(m,1H),3.53–3.48(m,1H),2.07–2.00(m,1H),1.98–1.92(m,1H),1.58–1.40(m,3H),1.04(d,J=6.3Hz,3H),0.87(dd,J=6.9,5.2Hz,6H),0.82–0.74(m,12H).
Compound 14: leu-Gly-Asp-Leu
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 18H32N4O7;m/z:417.23391([M+H]+).
1H NMR(600MHz,DMSO-d6)δ8.86(s,1H),8.55(d,J=7.2Hz,1H),7.73(d,J=7.8Hz,1H),4.37(q,J=7.1Hz,1H),4.02(q,J=7.5Hz,1H),3.91–3.80(m,1H),3.64–3.52(m,2H),2.54–2.49(m,1H),2.44–2.38(m,1H),1.66–1.57(m,2H),1.54–1.48(m,1H),1.48–1.37(m,3H),0.90–0.79(m,12H).
Compound 15: leu-Gly-Asp
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 12H21N3O6;m/z:304.14925([M+H]+).
1H NMR(600MHz,DMSO-d6)δ8.69(s,1H),7.87(d,J=6.9Hz,1H),4.22–4.14(m,1H),3.78(d,J=5.2Hz,2H),3.70(t,J=7.2Hz,1H),2.46(d,J=10.6Hz,1H),2.37–2.31(m,1H),1.70–1.63(m,1H),1.59–1.53(m,1H),1.51–1.45(m,1H),0.88(dd,J=10.4,6.5Hz,6H).
Compound 16: leu-Lys-Ser-Lys (acetate)
1H NMR(600MHz,DMSO-d6+D2O)δ4.35(t,J=6.7Hz,1H),4.17–4.12(m,1H),3.66–3.60(m,1H),3.56–3.50(m,1H),3.31(d,J=6.7Hz,1H),2.80–2.66(m,4H),1.84–1.45(m,19H,AcOH),1.45–1.11(m,7H),0.85–0.82(m,3H),0.80(d,J=6.6Hz,3H).
Compound 17: leu-Lys-Ser-Lys-Leu (acetate)
1H NMR(600MHz,DMSO-d6)δ8.53(d,J=7.7Hz,1H),8.13(s,1H),7.87(d,J=7.7Hz,1H),7.72(d,J=7.8Hz,1H),4.34(s,1H),4.26(q,J=6.1Hz,1H),4.21(q,J=6.8Hz,1H),3.89(td,J=8.4,5.1Hz,1H),3.64–3.49(m,2H),3.18(dd,J=9.1,5.0Hz,1H),2.75–2.61(m,4H),1.86–1.58(m,12H,AcOH),1.57–1.15(m,14H),0.88–0.79(m,12H).
Compound 18: val-Thr-Val-Ser-Val-Pro-Gly-Gly-Glu-Glu (acetate)
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 41H68N10O17;m/z:973.48858([M+H]+).
1H NMR(600MHz,DMSO-d6)δ8.62–8.50(m,2H),8.28(d,J=8.0Hz,1H),8.11(d,J=8.1Hz,1H),8.05(q,J=9.1,7.5Hz,2H),7.77(d,J=6.8Hz,1H),7.69(d,J=8.8Hz,1H),4.36–4.29(m,3H),4.24–4.18(m,3H),4.05–3.85(m,4H),3.80–3.67(m,3H),3.59(d,J=5.5Hz,1H),3.56–3.47(m,6H),2.25–2.16(m,4H),2.06–1.86(m,9H,AcOH),1.86–1.67(m,5H),1.03(d,J=6.3Hz,3H),0.90(d,J=6.9Hz,3H),0.86–0.73(m,16H).
Compound 19: val-Thr-Val-Ser-Ala-Pro-Gly-Gly-Glu-Glu (acetate)
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 39H64N10O17;m/z:945.45656([M+H]+).
1H NMR(600MHz,DMSO-d6)δ8.41–8.35(m,1H),8.32–8.26(m,1H),8.22(d,J=7.5Hz,1H),8.04(d,J=8.1Hz,1H),8.00(d,J=7.5Hz,1H),7.97(t,1H),7.87(d,J=6.9Hz,1H),7.76(d,J=8.6Hz,1H),4.58–4.49(m,1H),4.31(s,1H),4.29–4.18(m,4H),4.06–4.00(m,1H),4.00–3.95(m,1H),3.81–3.75(m,1H),3.70–3.62(m,3H),3.60(s,1H),3.53(d,J=5.8Hz,4H),3.45(d,J=4.8Hz,1H),2.22(q,J=7.3Hz,4H),2.07–1.74(m,14H,AcOH),1.74–1.67(m,1H),1.16(d,J=6.8Hz,3H),1.03(d,J=6.3Hz,3H),0.90(d,J=6.9Hz,3H),0.84–0.77(m,9H).
Compound 20:Val-Thr-Val-Ser-Leu-Ala-Gly-Gly-Glu
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 40H68N10O17;m/z:961.48753([M+H]+).
Compound 21: leu-Lys-Ser-Lys-Leu-Gly-Asp-Val-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
1H NMR(600MHz,D2O)δ4.45–4.26(m,10H),4.18–4.06(m,6H),4.01–3.91(m,6H),3.86–3.68(m,7H),3.64–3.57(m,1H),2.94(t,J=7.6Hz,4H),2.70–2.65(m,1H),2.60–2.55(m,1H),2.37–2.21(m,5H),2.11–1.82(m,20H,AcOH),1.82–1.31(m,23H),1.12(d,J=6.4Hz,3H),0.90–0.85(m,33H),0.82(d,J=5.4Hz,3H).
Compound 22: leu-Lys-Ser-Lys-Leu-Gly-Asp-Ala-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
1H NMR(600MHz,D2O)δ4.63–4.54(m,4H),4.45–4.25(m,9H),4.16–4.08(m,4H),4.00–3.88(m,6H),3.85–3.70(m,6H),3.60(q,J=7.4Hz,1H),2.94(t,J=7.6Hz,4H),2.71–2.64(m,1H),2.63–2.57(m,1H),2.36–2.21(m,5H),2.11–1.86(m,15H,AcOH),1.86–1.46(m,18H),1.44–1.35(m,4H),1.33(d,J=7.2Hz,3H),1.12(d,J=6.3Hz,3H),0.90–0.84(m,27H),0.82(d,J=5.6Hz,3H).
Compound 23: leu-Lys-Ser-Lys-Val-Gly-Asp-Val-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
1H NMR(600MHz,D2O)δ4.95–4.72(m,7H),4.60(m,3H),4.44–4.30(m,7H),4.18–4.06(m,5H),4.02(d,J=7.5Hz,1H),4.00–3.89(m,6H),3.88–3.68(m,6H),3.63–3.56(m,1H),2.93(t,J=7.8Hz,4H),2.71–2.66(m,1H),2.62–2.56(m,1H),2.39–2.29(m,4H),2.26–2.21(m,1H),2.11–1.84(m,29H,AcOH),1.83–1.74(m,2H),1.74–1.48(m,12H),1.44–1.30(m,4H),1.11(d,J=6.4Hz,3H),0.90–0.84(m,36H).
Compound 24: leu-Lys-Ser-Lys-Ala-Gly-Asp-Ala-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
1H NMR(600MHz,D2O)δ4.46–4.22(m,10H),4.17–4.09(m,4H),4.01–3.83(m,8H),3.81–3.70(m,4H),3.63–3.57(m,1H),2.97–2.92(m,4H),2.71–2.66(m,1H),2.65–2.59(m,1H),2.37–2.21(m,5H),2.12–1.85(m,16H,AcOH),1.84–1.48(m,14H),1.45–1.31(m,10H),1.13(d,J=6.4Hz,3H),0.91–0.85(m,24H). Compound 25: leu-Lys-Ser-Lys-Ile-Gly-Asp-Ile-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
High resolution mass spectrometry (TOF-HRMS), molecular formula :C81H140N20O28;m/z:921.51833([M+2H]2+),1842.02826([M+H]+).1H NMR(600MHz,D2O+DMSO-d6+TFA)δ4.63–4.53(m,3H),4.37–4.18(m,8H),4.17–4.08(m,4H),4.00(d,J=7.3Hz,1H),3.97–3.91(m,1H),3.80–3.57(m,8H),3.55–3.42(m,4H),2.84(s,1H),2.76–2.64(m,6H),2.58–2.51(m,1H),2.25(q,J=9.4,7.6Hz,4H),2.10–2.00(m,1H),1.99–1.59(m,23H,AcOH),1.59–1.44(m,10H),1.42–1.20(m,7H),1.05–0.90(m,5H),0.85–0.68(m,36H).
Compound 26: leu-Arg-Ser-Arg-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu
High resolution mass spectrometry (TOF-HRMS), compound :C33H61N9O11;m/z:633.35164([M+3H]3+),1898.04261([M+H]+). of formula 27: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Ala-Gly-Gly-Glu
High resolution mass spectrometry (TOF-HRMS), compound 28 of formula :C79H138N20O28;m/z:606.00885([M+3H]3+),1816.01835([M+H]+).: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Gly-Gly-Gly-Glu
High resolution mass spectrometry (TOF-HRMS), compound 29 of formula :C78H136N20O28;m/z:601.33780([M+3H]3+),1802.01155([M+H]+).: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Ala-Ala-Gly-Gly-Glu
High resolution mass spectrometry (TOF-HRMS), compound :C76H132N20O28;m/z:591.99278([M+3H]3+),1773.96555([M+H]+). of formula 30: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Asp
High resolution mass spectrometry (TOF-HRMS), compound 31 of formula :C80H138N20O28;m/z:610.00844([M+3H]3+),1828.01427([M+H]+).: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Gln-Glu
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 81H141N21O27;m/z:921.02784([M+2H]2+).
Compound 32: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Gln (acetate)
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 81H141N21O27;m/z:921.02807([M+2H]2+).
1H NMR(600MHz,D2O+DMSO-d6+TFA)δ4.88–4.73(m,6H),4.55–4.45(m,2H),4.31–4.25(m,3H),4.23–4.01(m,9H),3.99–3.93(m,1H),3.82–3.50(m,12H),3.45(s,1H),2.78–2.67(m,5H),2.66–2.59(m,1H),2.27(t,J=7.9Hz,2H),2.19–2.11(m,2H),2.11–1.72(m,16H,AcOH),1.71–1.17(m,26H),0.98(d,J=6.3Hz,3H),0.81–0.73(m,30H),0.71(t,J=7.0Hz,6H).
Compound 34: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly (acetate)
1H NMR(600MHz,D2O+DMSO-d6+TFA)δ4.57–4.44(m,3H),4.35–4.21(m,7H),4.19–4.15(m,1H),4.11(q,J=4.6,3.9Hz,2H),4.07(d,J=7.5Hz,1H),4.00–3.93(m,1H),3.83–3.46(m,11H),2.80–2.69(m,5H),2.67–2.60(m,1H),2.10–1.75(m,13H,AcOH),1.74–1.20(m,26H),0.99(d,J=6.3Hz,3H),0.83–0.75(m,30H),0.72(dd,J=9.1,6.1Hz,6H).
Compound 35: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly (acetate)
1H NMR(600MHz,D2O)δ4.62-4.49(m,4H),4.44–4.33(m,4H),4.33–4.24(m,4H),4.15–4.07(m,3H),4.00–3.66(m,12H),3.64–3.56(m,1H),2.94(t,J=7.7Hz,4H),2.68–2.62(m,1H),2.59–2.51(m,1H),2.28–2.21(m,1H),2.07–1.49(m,32H,AcOH),1.45–1.33(m,4H),1.12(d,J=6.3Hz,3H),0.90–0.85(m,30H),0.81(t,J=6.6Hz,6H).
Compound 36: leu-Lys-Ser-Lys-Leu-Gly-Glu-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
1H NMR(600MHz,D2O)δ4.52–4.23(m,11H),4.15–4.08(m,4H),4.00–3.87(m,6H),3.86–3.67(m,6H),3.63–3.56(m,1H),2.96–2.91(m,4H),2.35–2.19(m,7H),2.11–1.46(m,40H,AcOH),1.44–1.32(m,4H),1.11(d,J=6.4Hz,3H),0.90–0.84(m,30H),0.81(t,J=6.3Hz,6H).
Compound 37: leu-Lys-Ser-Lys-Leu-Gly-Asn-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
1H NMR(600MHz,D2O+TFA)δ4.48(s,1H),4.43(d,J=8.4Hz,1H),4.28–4.13(m,8H),4.10(d,J=6.0Hz,2H),4.00–3.92(m,3H),3.82–3.51(m,12H),3.42(s,1H),2.80–2.71(m,5H),2.60–2.55(m,1H),2.54–2.47(m,1H),2.45(s,3H),2.25(t,J=7.2Hz,4H),2.10–1.29(m,39H,AcOH),1.21(s,4H),0.94(d,J=6.4Hz,3H),0.74–0.68(m,30H),0.64(t,J=6.1Hz,6H).
Compound 39: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Ala-Pro-Gly-Gly-Glu-Glu (acetate)
1H NMR(600MHz,D2O+DMSO-d6+TFA)δ4.37–4.11(m,13H),3.96(dd,J=6.4,4.5Hz,1H),3.79–3.47(m,13H),2.77–2.63(m,5H),2.29–2.20(m,4H),2.11–1.21(m,42H,AcOH),1.15(d,J=6.8Hz,3H),0.98(d,J=6.3Hz,3H),0.86–0.76(m,30H).
Compound 40: val-Lys-Thr-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 81H140N20O28;m/z:921.52020([M+2H]2+),1842.0936([M+H]+) compound 41: val-Lys-Thr-Lys-Val-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu
High resolution mass spectrometry (TOF-HRMS), molecular formula :C80H138N20O28;m/z:610.00824([M+3H]3+),914.51043([M+2H]2+),1828.01136([M+H]+).
Compound 42: ala-Lys-Ala-Lys-Ala-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 75H128N20O27;m/z:871.47546([M+2H]2+).
Compound 43: val-Lys-Ala-Lys-Val-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu
High resolution mass spectrometry (TOF-HRMS), molecular formula :C79H136N20O27;m/z:600.00616([M+3H]3+),899.50814([M+2H]2+),1798.00999([M+H]+).
Compound 44: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Asp-Asp (acetate)
1H NMR(600MHz,D2O+DMSO-d6+TFA)δ4.61–4.45(m,4H),4.36–4.16(m,11H),3.80–3.74(m,3H),3.71–3.65(m,6H),3.64–3.56(m,3H),3.53–3.45(m,4H),2.77–2.61(m,7H),2.59–2.51(m,1H),2.46–2.41(m,1H),2.08–1.76(m,11H),1.73–1.14(m,26H),0.97(d,J=6.3Hz,3H),0.88–0.76(m,36H).
Compound 45: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Ala-Ala-Asp-Asp (acetate)
High resolution mass spectrometry (TOF-HRMS), molecular formula :C81H140N20O28;m/z:614.68030([M+3H]3+),921.51901([M+2H]2+),1842.02875([M+H]+).
1H NMR(600MHz,D2O+DMSO-d6+TFA)δ4.56–4.46(m,4H),4.37–4.10(m,23H),3.77(t,J=7.3Hz,1H),3.67(s,2H),3.62–3.56(m,2H),3.53–3.44(m,4H),2.77–2.54(m,8H),2.47–2.44(m,1H),2.07–1.74(m,15H,AcOH),1.73–1.14(m,31H),0.97(d,J=6.3Hz,3H),0.88–0.76(m,36H).
Compound 46: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Ala-Ala-Gln
High resolution mass spectrometry (TOF-HRMS), compound :C83H146N22O26;m/z:623.36767([M+3H]3+),1868.08748([M+H]+). of formula 47: leu-Lys-Ser-Lys-Leu-Pro-Val-Pro-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
1H NMR(600MHz,D2O+DMSO-d6+TFA)δ4.53(t,J=7.1Hz,1H),4.49–4.44(m,1H),4.41–4.12(m,16H),3.79–3.41(m,18H),2.72(q,J=7.6Hz,4H),2.28–2.20(m,4H),2.06–1.23(m,50H,AcOH),0.98(d,J=6.3Hz,3H),0.88–0.76(m,36H).
Compound 48: leu-Lys-Ser-Lys-Leu-Ala-Asp-Val-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
1H NMR(600MHz,D2O+DMSO-d6+TFA)δ4.52(q,J=7.1Hz,2H),4.35–4.12(m,15H),3.79–3.56(m,9H),3.52–3.44(m,4H),2.76–2.65(m,5H),2.29–2.20(m,4H),2.07–1.23(m,40H,AcOH),1.18(d,J=7.1Hz,3H),0.97(d,J=6.3Hz,3H),0.88–0.73(m,36H).
Compound 49: leu-Lys-Ser-Lys-Leu-Ala-Glu-Val-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
1H NMR(600MHz,D2O+DMSO-d6+TFA)δ4.54-4.47(m,1H),4.31–4.10(m,14H),3.95(dd,J=6.4,4.4Hz,1H),3.78–3.56(m,7H),3.54–3.42(m,4H),2.85(s,1H),2.76–2.70(m,4H),2.69(s,1H),2.29–2.12(m,6H),2.07–1.23(m,43H,AcOH),1.18(d,J=7.1Hz,3H),0.97(d,J=6.3Hz,3H),0.86–0.74(m,36H).
Compound 50: leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
1H NMR(600MHz,D2O+TFA)δ4.49–4.45(m,1H),4.31–4.18(m,5H),4.04(d,J=8.2Hz,1H),3.99(d,J=7.3Hz,1H),3.95(dd,J=6.5,5.4Hz,1H),3.88(t,J=7.4Hz,1H),3.82–3.72(m,4H),3.67–3.55(m,3H),3.48–3.42(m,1H),2.33–2.26(m,4H),2.14–1.70(m,15H,AcOH),1.58–1.31(m,5H),0.97(d,J=6.4Hz,3H),0.77–0.69(m,24H).
Compound 51: leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Val-Gly-Gly-Glu-Glu (acetate)
High resolution mass spectrometry (TOF-HRMS), molecular formula :C81H142N20O28;m/z:615.35313([M+3H]3+),922.52805([M+2H]2+),1844.05005([M+H]+).
Compound 52: lys-Leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
High resolution mass spectrometry (TOF-HRMS), molecular formula :C87H152N22O29;m/z:657.38043([M+3H]3+),1970.13025([M+H]+).1H NMR(600MHz,D2O)δ4.64–4.53(m,6H),4.45–4.23(m,11H),4.16–4.08(m,4H),3.99–3.87(m,6H),3.85–3.69(m,6H),3.64–3.56(m,1H),2.97–2.92(m,6H),2.70–2.64(m,1H),2.61–2.54(m,1H),2.35–2.21(m,5H),2.12–1.73(m,23H,AcOH),1.73–1.49(m,20H),1.45–1.33(m,6H),1.12(d,J=6.4Hz,3H),0.89–0.80(m,36H).
Compound 53: pro-Val-Pro-Leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate) )1H NMR(600MHz,D2O)δ4.62–4.53(m,6H),4.47–4.22(m,15H),4.16–4.08(m,4H),3.97–3.87(m,5H),3.86–3.69(m,7H),3.66–3.56(m,2H),3.42–3.29(m,2H),2.97–2.89(m,4H),2.70–2.64(m,1H),2.62–2.54(m,1H),2.44–2.18(m,7H),2.11–1.72(m,27H,AcOH),1.71–1.47(m,19H),1.43–1.31(m,4H),1.11(d,J=6.4Hz,3H),0.95(d,J=6.7Hz,3H),0.90–0.79(m,42H).
Compound 54: lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (acetate)
High resolution mass spectrometry (TOF-HRMS), molecular formula :C75H129N19O27;m/z:864.97732([M+2H]2+),1728.94810([M+H]+).1H NMR(600MHz,D2O+CD3OD)δ4.61–4.48(m,5H),4.45–4.35(m,2H),4.32–4.22(m,5H),4.21–4.16(m,1H),4.12–4.04(m,4H),3.96(t,J=6.7Hz,1H),3.92–3.64(m,11H),3.58–3.51(m,1H),2.90(q,J=7.7Hz,4H),2.68–2.60(m,1H),2.59–2.52(m,1H),2.33–2.14(m,5H),2.06–1.28(m,40H,AcOH),1.07(d,J=6.4Hz,3H),0.85–0.75(m,31H).
Compound 55: leu-Lys-Ser-Lys-Leu-Gly-Asp (acetate)
High resolution mass spectrometry (TOF-HRMS), molecular formula: c 33H61N9O11;m/z:380.73248([M+2H]2+),760.45776([M+H]+).
1H NMR(600MHz,D2O)δ4.44–4.25(m,5H),4.01–3.93(m,2H),3.88–3.75(m,3H),2.94(q,J=7.3Hz,4H),2.73–2.65(m,1H),2.62–2.53(m,1H),1.94(s,8H,AcOH),1.84–1.50(m,14H),1.46–1.31(m,4H),0.92–0.85(m,9H),0.82(d,J=5.4Hz,3H).
EXAMPLE 2 promotion of HaCAT cell proliferation by polypeptide Compound 1 and related Polypeptides
The experimental method is to adjust the concentration of human immortalized keratinocytes (HaCaT cells) to 1.0X10 5~5.0×105/mL for subculture, and culture at 37 ℃ under the condition of 5% CO 2 for 24-36 hours for biological activity detection. Cells were digested with pancreatin and collected, inoculated in 96-well cell culture plates at a concentration of 2.5X10 4/mL with serum-free medium, 100. Mu.L per well, and cultured overnight at 37℃under 5% CO 2. Adding 50 mu L of polypeptide compound solutions with different concentrations prepared by using a serum-free culture medium, so that the final concentration of the polypeptide compound to be detected is 0.2ug/mL; simultaneously setting an EGF control group, namely adding 50 mu L of recombinant human Epidermal Growth Factor (EGF) solution prepared by a serum-free culture medium, wherein the final concentration is 100ng/mL; model control, i.e., an equal volume of serum-free medium was added. Culturing at 37deg.C under 5% CO2 for 72 hr, using CellTiter-The kit detects the proliferation of the HaCaT cell strain.
Results: statistical analysis of the test results is shown in Table 4. The effect of the polypeptide compound 1 and related polypeptide on promoting the proliferation of HaCaT cells has strong and weak variability. The polypeptide H308 has no proliferation promoting effect, while other polypeptides have remarkable proliferation promoting effect, which indicates that the polypeptide compound 1 and related polypeptides have potential application value in the aspect of skin related diseases.
Table 4 proliferation promoting effect of polypeptides on HaCaT cells
Note that:
-no pro-proliferative effect;
Calculated by taking the proliferation rate of a blank control group as 100%, the proliferation rate is 120-150%; ++ represents that the proliferation rate is 150-200%; the++ represents that the proliferation rate is 200-250%; the proliferation rate is 250-300%
Experimental example 3 wound repair action of polypeptide Compound 1 on acute mechanical injury animal model
SPF SD rats (weight of 180-230 g) are respectively fed into clean disinfection cages, water, feed and padding are regularly fed every day, the feeding temperature is kept at 22 ℃, the humidity is kept at 55-65%, and the rats are fed for one week to adapt to the environment. After the rats are successfully anesthetized by 3% pentobarbital sodium intraperitoneal injection, the hairs at 1cm of the edge of the wound are cut off, firstly, the wound area is disinfected by iodophor, then the wound area is disinfected locally by 75% alcohol, and a circular full-layer skin wound of 1.5cm multiplied by 1.5cm (i.e. the diameter is 1.5 cm) is made by taking the spine as a midline position from the middle of an ear connecting line to the lower 4cm of the neck side of the back and the depth to the muscular layer. The surrounding skin is fixed by a rubber ring to form an animal model of acute mechanical injury. After molding, the wound of the rat is exposed, and the rat is fed in a single cage. A model control group (physiological saline), an EGF control group (trade name: jin Yintai), a compound 1 treatment group (high and low dose, concentration of 2, 0.4mg/mL, respectively) were set, 6 in each group. When changing the dressing, firstly, the wound is debrided by iodophor, and then the wound is flushed by sterile normal saline and wiped dry. The medicine is administrated locally for 1 time every day, 35 mu L of medicine is dripped into the wound surface, and the medicine is continuously administrated for 14+ days.
The monitoring of body weight and observation of wound surface (including the condition of red swelling, exudates and infection, wound shrinkage, surface scab and new epidermis) are carried out 1 time a day. The results obtained are as follows:
(1) The body weight of the rats is monitored regularly in the research process, and the results show that the body weight of the rats is in a normal growth state, and the body weights of the rats in each group have no obvious difference.
(2) On days 0, 10 and 14 after modeling, taking wound images of each group of rats, calculating the wound area by adopting Image analysis software (Image J), and obtaining the wound healing rate according to a formula. And finally, analyzing whether the healing rate of each group has statistical significance by using statistical analysis software. The wound healing rate results are shown in Table 5.
TABLE 5 wound healing Rate (%)
Group of | Day 0 of administration | Day 10 of administration | Day 14 of administration |
Model control group | 0.00±0.00 | 13.51±7.20 | 61.96±7.55 |
EGF control group | 0.00±0.00 | 26.52±9.46 | 72.88±2.63 |
Compound 1 low dose group | 0.00±0.00 | 35.99±2.47 | 73.79±6.51 |
Compound 1 high dose group | 0.00±0.00 | 35.60±6.54 | 84.20±1.00* |
Note that: * Represents P <0.05 relative to the model control group
Table 5 the results show that the high dose group of polypeptide compound 1 has a significant wound healing promoting effect (P < 0.05) compared to the model control group.
EXAMPLE 4 repair of skin wounds in mice by novel polypeptide Compound 1
The test method comprises the following steps: 60 male Kunming mice (purchased from Beijing Bei Fu Biotechnology Co.) were selected for 8-10 weeks and kept in separate cages for free feeding, and feeding was stopped the day before the test. The anaesthetized mice are injected with 0.2ml sodium pentobarbital with mass fraction of 1% to the abdominal cavity, the back shearing is carried out, square wounds of 0.5cm x 0.5cm are symmetrically arranged on the upper and lower parts of the skin of the epidermis of the spine, the whole skin is sheared off, no injury and muscle layer are caused, and the wound is haemostatic for standby. The next day, the mice were anesthetized with diethyl ether, compound 1 (0.15 mg/ml or 0.30 mg/ml) of different solution concentrations, physiological saline and new rehabilitation solution were added dropwise to the wound, each 0.1ml was changed once daily, and wound healing was observed on days 4, 7, 11. The wound healing rate was calculated as follows: wound healing rate (%) = (original wound area-unhealed wound area)/original wound area. The results are shown in Table 6.
TABLE 6 statistical results of wound healing Rate in mice
Note that: significant differences in P <0.05 compared to model group
The test result shows that the novel polypeptide compound 1 can obviously promote the healing of skin wounds of mice, has obvious difference compared with a control group, and is superior to a rehabilitation solution.
Example 5: antiulcer effect of partial polypeptide sample obtained in example 1 on ethanol-induced gastric ulcer model of mice
1. Experimental animals: SPF-grade C57BL/6 mice, chengdu Biotechnology Co., ltd., animal license number: SCXK (Chuan) 2020-034
2. The method comprises the following steps:
Following adaptive feeding of the experimental animals, all animals began to fasted and not water-forbidden for 24 hours after 1 day of dosing prior to the experiment. Experimental mice were randomly grouped prior to modeling: 5 blank groups, 10 model groups, 10 teprenone groups and 10 polypeptide compound administration groups, except for the blank groups and the model groups, purified water is administrated by gastric lavage, the teprenone groups are administrated by different test samples according to the gastric lavage of 160mg/kg, the polypeptide administration groups are administrated by the gastric lavage of 0.2mg/kg for 1 hour, the mice of each group are administrated by the oral gastric lavage of 0.9ml/kg for molding, animals are sacrificed by a cervical method after 1 hour, and pylorus are ligated and clamped, and the whole stomach is extracted. 1mL of 1% formaldehyde solution is injected into the stomach body, the cardia is ligated, and the stomach is taken out and then put into the 1% formaldehyde solution. After soaking for 30min, taking out the stomach tissue, cutting along the greater curvature of the stomach, flushing the stomach content with normal saline, observing and measuring the damage of the gastric mucosa of the mice after tiling, calculating the ulcer index and the ulcer inhibition rate, and taking a panoramic picture of the stomach.
The method for calculating the ulcer index comprises the following steps: the length of the strip-shaped injury is greater than 1mm, and the length is measured to be 1 minute per millimeter; if the width is larger than 1mm, doubling the score according to the millimeter number of the width; the length was less than 1mm for 0.5 minutes and the scores were added to give the animal an ulcer index.
Percent inhibition of ulcers = (model group ulcer index-dosing group ulcer index)/model group ulcer index x 100%;
Relative ulcer inhibition = (test compound ulcer inhibition)/(compound 1 ulcer inhibition).
3. Results: table 7 shows the relative ulcer inhibition of the compounds of the present invention:
TABLE 7 relative ulcer inhibition of the compounds of the invention
/>
* Annotation:
the antiulcer effect of the series of compounds was accomplished in a number of experiments and was expressed as relative ulcer inhibition for ease of comparison.
The ulcer index was negative over the model group, indicated as "-"; the ulcer index was positive below the model group, indicated as "+".
Each test was run with compound 1 as a control, let the relative ulcer inhibition of compound 1 be 1, denoted as' ++ ";
the relative ulcer inhibition rate was >1.20, denoted as' ++ ";
The relative ulcer inhibition rate is 0.9-1.20, denoted as' ++ ";
the relative ulcer inhibition rate is 0.6-0.9, which is expressed as "++";
The relative ulcer inhibition rate is 0.3-0.6, which is expressed as "+";
Relative ulcer inhibition was <0.3, indicated as "/" (very low activity).
EXAMPLE 6 therapeutic Effect of novel polypeptide Compound 1 on stress gastric ulcer in rats
The test method comprises the following steps: 75 male SD rats weighing 180-210 g (purchased from Beijing Bei Fu Biotechnology Co., ltd.) were selected and subjected to cage-division adaptive rearing for 1 week, and then randomly divided into a blank group, a model group, a sucralfate group (1 g/kg, a positive drug group), a compound 1 low dose group (1.5 mg/kg) and a high dose group (3.0 mg/kg). The administration group is administrated by stomach irrigation. The rats of each group are fixed on a rat board by adopting a constrained water immersion method except a control group, and are immersed in a constant-temperature water tank with the temperature of 20 ℃ for 8 hours vertically in the head direction, so that the water surface is flush with the xiphoid process of the rats. After the stress modeling is finished, the cervical dislocation of the rat is killed, and the pylorus is ligated after laparotomy. 2ml of formaldehyde solution with the volume fraction of 10% is poured into the stomach, the cardia is ligated, and the stomach body is taken out and fixed in the formaldehyde solution for 15 minutes. Cut along the greater curvature of the stomach, and after flushing with normal saline, the gastric mucosa is observed for loss and gastric ulcer index is calculated. The Ulcer Index (UI) was calculated according to Guth standard: the punctate hemorrhages were 1 minute, the linear hemorrhages were 2 minutes for length <1mm, 4 minutes for 2-4 mm, > 5 minutes for 4mm, and the time scores were 2 for width >1 mm. The results are shown in Table 8.
TABLE 8 statistical results of gastric ulcer index of rats
/>
Note that: significant differences in P <0.01 compared to model group
The test result shows that the novel polypeptide compound 1 has obvious protection effect on the stress gastric ulcer of rats, has obvious difference compared with a model group, and has better protection effect than the positive drug sucralfate.
Example 7 gastric and intestinal stability test and post-disinfectant treatment stability of partial polypeptide samples
The method comprises the following steps: 1mg of each sample to be tested (Compound 1, compound 2, compound 3, compound 5, compound 18, compound 19 and control EGF)) was taken and dissolved in 1ml of water. 100ul of sample solution is taken, 900ul of water is added, and the mixture is uniformly mixed to be used as a reference substance solution. 100ul of each sample solution is added with artificial gastric juice (W), artificial intestinal juice (X), povidone iodine solution (I) and hydrogen peroxide solution (O) 900ul respectively, the mixture is cooled in a constant-temperature water bath at 37 ℃ for 1 hour, filtered, and the peak areas of the samples before and after treatment are detected by high performance liquid chromatography respectively as sample solutions to be tested, and the test results are calculated by comparing the peak areas of the samples. Taking stock solution which is diluted by water and does not undergo any treatment as a control, and comparing and counting the peak area (content) change condition of corresponding positions of other test sample solutions.
Table 9 stability test of polypeptide samples after gastric, intestinal, in vitro disinfectant treatment
Numbering device | W remains% | X retention% | I retention% | O retention% |
EGF | 0 | 0 | 0 | 0 |
Compound 1 | 0 | 0 | 106 | 104 |
Compound 2 | 0 | 56 | 99 | 99 |
Compound 3 | 0 | 63 | 101 | 99 |
Compound 5 | 99 | 100 | 98 | 100 |
Compound 18 | 99 | 100 | 99 | 100 |
Compound 19 | 101 | 100 | 99 | 98 |
Note that: w represents artificial gastric juice, X represents artificial intestinal juice, I represents povidone-iodine solution, O represents hydrogen peroxide solution
Results: as shown in table 9, samples of test compounds 1,2, 3, 5, 18, 19 remained at 100% in both povidone-iodine solution (I) and hydrogen peroxide solution (O), indicating that they can be used with disinfectants and are stable after disinfection treatment; the compounds 5, 18 and 19 are stable to the artificial gastric juice (W) and the artificial intestinal juice (X), and the compounds 2 and 3 are stable to the artificial intestinal juice (X); EGF was not retained in both gastric and intestinal fluids, indicating that the topical application of EGF after sterilization with povidone-iodine and hydrogen peroxide solutions was also destroyed.
Although the present invention has been described in terms of the foregoing embodiments, the present invention is not limited to the embodiments described above, but is capable of other modifications, adaptations, alternatives, combinations, and simplifications without departing from the scope of the invention.
Claims (5)
1. A compound or a physiologically compatible salt thereof, wherein the compound is selected from the group consisting of:
Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 2);
Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 3);
Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 5);
Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu (Compound 10);
Gly-Asp-Leu-Val-Thr-Val-Ser-Leu (Compound 11);
Val-Thr-Val-Ser-Leu-Pro (Compound 12);
Val-Thr-Val-Ser-Leu (Compound 13);
Val-Thr-Val-Ser-Leu-Ala-Gly-Gly-Glu-Glu (Compound 20);
Leu-Lys-Ser-Lys-Leu-Gly-Asp-Val-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 21); leu-Lys-Ser-Lys-Val-Gly-Asp-Val-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 23); leu-Lys-Ser-Lys-Ile-Gly-Asp-Ile-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 25); leu-Arg-Ser-Arg-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 26); leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Ala-Gly-Gly-Glu-Glu (Compound 27); leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Gly-Gly-Gly-Glu-Glu (Compound 28); leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Gln-Glu (Compound 31); leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Gln (Compound 32); gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly (Compound 33);
Leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly (Compound 35);
Leu-Lys-Ser-Lys-Leu-Gly-Glu-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 36); leu-Lys-Ser-Lys-Leu-Gly-Asn-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 37); leu-Lys-Ser-Lys-Leu-Pro-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 38); val-Lys-Thr-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 40); ala-Lys-Ala-Lys-Ala-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 42); val-Lys-Ala-Lys-Val-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 43); leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Asp-Asp (Compound 44); leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Ala-Ala-Asp-Asp (Compound 45); leu-Lys-Ser-Lys-Leu-Pro-Val-Pro-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 47); leu-Lys-Ser-Lys-Leu-Ala-Glu-Val-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 49); leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 50);
Leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Val-Gly-Gly-Glu-Glu (Compound 51);
Pro-Val-Pro-Leu-Lys-Ser-Lys-Leu-Gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 53).
2. Use of a compound of claim 1, or a physiologically compatible salt thereof, in the manufacture of a medicament for the prevention of gastric ulcers.
3. Use of a compound of claim 1, or a physiologically compatible salt thereof, in the manufacture of a medicament for repairing skin wounds; the compound is as follows: gly-Asp-Leu-Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 3);
Val-Thr-Val-Ser-Leu-Pro-Gly-Gly-Glu-Glu (Compound 5); val-Thr-Val-Ser-Leu (Compound 13).
4. The use according to claim 3, wherein the skin wound is associated with diseases of epidermal inflammation, mechanical and surgical wounds, burns and scalds, ulcers, fistulas, bedsores, skin lesions caused by chemoradiotherapy.
5. A pharmaceutical composition comprising a compound of claim 1 or a physiologically compatible salt thereof and a physiologically acceptable carrier.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020108733773 | 2020-08-26 | ||
CN202010873377 | 2020-08-26 | ||
CN202110984908.0A CN114106100B (en) | 2020-08-26 | 2021-08-25 | Polypeptide for repairing skin wound or mucous membrane injury and application thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110984908.0A Division CN114106100B (en) | 2020-08-26 | 2021-08-25 | Polypeptide for repairing skin wound or mucous membrane injury and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118221777A true CN118221777A (en) | 2024-06-21 |
Family
ID=80354641
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110984908.0A Active CN114106100B (en) | 2020-08-26 | 2021-08-25 | Polypeptide for repairing skin wound or mucous membrane injury and application thereof |
CN202410392675.9A Pending CN118221777A (en) | 2020-08-26 | 2021-08-25 | Polypeptide for repairing skin wound or mucous membrane injury and application thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110984908.0A Active CN114106100B (en) | 2020-08-26 | 2021-08-25 | Polypeptide for repairing skin wound or mucous membrane injury and application thereof |
Country Status (3)
Country | Link |
---|---|
CN (2) | CN114106100B (en) |
TW (1) | TW202207967A (en) |
WO (1) | WO2022042590A1 (en) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2982078B2 (en) * | 1990-10-05 | 1999-11-22 | アース製薬株式会社 | Canine epidermal growth factor, anti-inflammatory agent or cosmetic containing the canine epidermal growth factor as an active ingredient, and method for producing canine epidermal growth factor cEGF |
DE69329760D1 (en) * | 1992-09-15 | 2001-01-18 | Creative Biomolecules Inc | TREATMENT OF STOMACH AND COLUMN Ulcers WITH MORPHOGENES |
CN102657845B (en) * | 2012-05-31 | 2013-09-11 | 中国科学院昆明动物研究所 | Applications of odorrana grahami polypeptide AH90 and CW49 for promoting skin regeneration |
KR20180006362A (en) * | 2014-12-09 | 2018-01-17 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Methods of promoting tissue healing and repair |
EP3305802B1 (en) * | 2015-05-26 | 2021-05-12 | Gemvax & Kael Co., Ltd. | Anti-inflammatory, anti-fibrotic and wound-healing octapeptides and compositions containing the same |
CN108586575B (en) * | 2018-04-11 | 2020-08-14 | 福建省中科生物股份有限公司 | Polypeptide and application of polypeptide in skin repair function |
CN108530527B (en) * | 2018-04-23 | 2019-07-12 | 昆明医科大学 | Polypeptide OA-GL21 and purification method and application thereof |
CN108586576B (en) * | 2018-04-23 | 2019-07-12 | 昆明医科大学 | A kind of polypeptide OA-FF10 and its method of purification and application |
CN109320591B (en) * | 2018-10-26 | 2021-06-01 | 昆明医科大学 | Polypeptide OA-GL12 and application thereof |
CN110563811B (en) * | 2019-09-25 | 2022-05-10 | 昆明医科大学 | Skin protection peptide HW-P1 and preparation method and application thereof |
CN110642924B (en) * | 2019-10-12 | 2022-10-28 | 杨莹 | Skin protection peptide OM-TV16 and preparation method and application thereof |
CN110606872B (en) * | 2019-10-12 | 2022-06-21 | 珠海市雅莎医疗器械有限公司 | Antioxidant polypeptide OA-GL17 for promoting skin wound repair and preparation method and application thereof |
JP7531082B2 (en) * | 2020-07-01 | 2024-08-09 | スーチョワン グッドドクター パンシー ファーマシューティカル カンパニー リミテッド | Polypeptides for repairing mucosal injury or skin wounds and uses thereof |
-
2021
- 2021-08-25 CN CN202110984908.0A patent/CN114106100B/en active Active
- 2021-08-25 CN CN202410392675.9A patent/CN118221777A/en active Pending
- 2021-08-25 WO PCT/CN2021/114499 patent/WO2022042590A1/en active Application Filing
- 2021-08-25 TW TW110131495A patent/TW202207967A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202207967A (en) | 2022-03-01 |
CN114106100B (en) | 2024-05-17 |
WO2022042590A1 (en) | 2022-03-03 |
CN114106100A (en) | 2022-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5913117B2 (en) | Hatching fluid enzyme and use thereof | |
WO2019228307A1 (en) | New pharmaceutical use | |
JP7531082B2 (en) | Polypeptides for repairing mucosal injury or skin wounds and uses thereof | |
WO2017009488A1 (en) | Topical compositions | |
PT1462455E (en) | Ser-ser-ser-arg peptide and medicinal uses thereof | |
WO2022148289A1 (en) | Polypeptide for repairing skin wound or mucosal injury, and application thereof | |
CN114106100B (en) | Polypeptide for repairing skin wound or mucous membrane injury and application thereof | |
JP7511296B2 (en) | Peptides and cosmetic and pharmaceutical compositions containing same | |
CN114716515A (en) | Polypeptide analogue and preparation method and application thereof | |
KR102091567B1 (en) | Pharmaceutical composition for prevention or treatment of brain injury comprising the osteopontin protein fragment as an active ingredient | |
WO2023125770A1 (en) | Application of polypeptide in preparation of product for preventing or treating skin injury diseases | |
CN116003529A (en) | Polypeptide and application thereof in repairing mucous membrane injury or skin injury | |
CN114621323B (en) | Polypeptide compound with skin repairing effect and preparation method and application thereof | |
CN114478695B (en) | New polypeptide for promoting tissue repair and application thereof | |
CN112876535B (en) | Bioactive polypeptides and uses thereof | |
KR20240130115A (en) | Use of a polypeptide in the manufacture of a product for preventing or treating skin damage disorders | |
EP3925626A1 (en) | Lipopeptide conjugates and their salts, method of manufacture of lipopeptide conjugates and their salts, pharmaceutical composition comprising a lipopeptide conjugate and its salts for the treatment of chronic wounds | |
JP2006063033A (en) | Composition containing cell migration promotion activity polypeptide | |
KR20190056106A (en) | Use of a peptide as a therapeutic agent for wound healing | |
KR20190056110A (en) | Use of a peptide as a therapeutic agent for wound healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |